Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study.
Identifieur interne : 000999 ( Main/Exploration ); précédent : 000998; suivant : 000A00Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study.
Auteurs : B. Dréno [France] ; A. Ribas [États-Unis] ; J. Larkin [Royaume-Uni] ; P A Ascierto [Italie] ; A. Hauschild [Allemagne] ; L. Thomas [France] ; J-J Grob [France] ; D O Koralek [États-Unis] ; I. Rooney [États-Unis] ; J J Hsu [États-Unis] ; E F Mckenna [États-Unis] ; G A Mcarthur [Australie]Source :
- Annals of oncology : official journal of the European Society for Medical Oncology [ 1569-8041 ] ; 2017.
Abstract
In the coBRIM phase III trial, the addition of cobimetinib, an MEK inhibitor, to vemurafenib, a BRAF inhibitor, significantly improved progression-free survival [hazard ratio (HR), 0.58; P < 0.0001] and overall survival (HR, 0.70; P = 0.005) in advanced BRAF-mutated melanoma. Here, we report on the incidence, course, and management of key adverse events (AEs) in the coBRIM study.
DOI: 10.1093/annonc/mdx040
PubMed: 28444112
Affiliations:
- Allemagne, Australie, France, Italie, Royaume-Uni, États-Unis
- Angleterre, Californie, Grand Londres, Pays de la Loire, Provence-Alpes-Côte d'Azur, Schleswig-Holstein, Victoria (État)
- Kiel, Londres, Los Angeles, Marseille, Melbourne, Nantes
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000D02
- to stream PubMed, to step Curation: 000C99
- to stream PubMed, to step Checkpoint: 000C99
- to stream Ncbi, to step Merge: 004695
- to stream Ncbi, to step Curation: 004695
- to stream Ncbi, to step Checkpoint: 004695
- to stream Main, to step Merge: 000994
- to stream Main, to step Curation: 000999
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study.</title><author><name sortKey="Dreno, B" sort="Dreno, B" uniqKey="Dreno B" first="B" last="Dréno">B. Dréno</name><affiliation wicri:level="3"><nlm:affiliation>Department of Dermato Cancerology, Nantes University, Nantes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Dermato Cancerology, Nantes University, Nantes</wicri:regionArea><placeName><region type="region">Pays de la Loire</region><region type="old region">Pays de la Loire</region><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name sortKey="Ribas, A" sort="Ribas, A" uniqKey="Ribas A" first="A" last="Ribas">A. Ribas</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medicine, Hematology/Oncology, Jonsson Comprehensive Cancer Center, The University of California, Los Angeles, Los Angeles, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Hematology/Oncology, Jonsson Comprehensive Cancer Center, The University of California, Los Angeles, Los Angeles</wicri:regionArea><placeName><settlement type="city">Los Angeles</settlement><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Larkin, J" sort="Larkin, J" uniqKey="Larkin J" first="J" last="Larkin">J. Larkin</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medicine, Royal Marsden NHS Foundation Trust, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Medicine, Royal Marsden NHS Foundation Trust, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Ascierto, P A" sort="Ascierto, P A" uniqKey="Ascierto P" first="P A" last="Ascierto">P A Ascierto</name><affiliation wicri:level="1"><nlm:affiliation>Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori Fondazione G. Pascale, Naples</wicri:regionArea><wicri:noRegion>Naples</wicri:noRegion></affiliation></author><author><name sortKey="Hauschild, A" sort="Hauschild, A" uniqKey="Hauschild A" first="A" last="Hauschild">A. Hauschild</name><affiliation wicri:level="3"><nlm:affiliation>Department of Dermatology, University Hospital Schleswig-Holstein, Kiel, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Dermatology, University Hospital Schleswig-Holstein, Kiel</wicri:regionArea><placeName><region type="land" nuts="2">Schleswig-Holstein</region><settlement type="city">Kiel</settlement></placeName></affiliation></author><author><name sortKey="Thomas, L" sort="Thomas, L" uniqKey="Thomas L" first="L" last="Thomas">L. Thomas</name><affiliation wicri:level="1"><nlm:affiliation>Department of Dermatology, Centre Hospitalier Lyon Sud, Lyon 1 University, Lyons Cancer Research Center, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Dermatology, Centre Hospitalier Lyon Sud, Lyon 1 University, Lyons Cancer Research Center</wicri:regionArea><wicri:noRegion>Lyons Cancer Research Center</wicri:noRegion><wicri:noRegion>Lyons Cancer Research Center</wicri:noRegion></affiliation></author><author><name sortKey="Grob, J J" sort="Grob, J J" uniqKey="Grob J" first="J-J" last="Grob">J-J Grob</name><affiliation wicri:level="3"><nlm:affiliation>Dermatology and Cutaneous Oncology, Aix-Marseille University Hôpital de la Timone AP-HM, Marseille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Dermatology and Cutaneous Oncology, Aix-Marseille University Hôpital de la Timone AP-HM, Marseille</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Koralek, D O" sort="Koralek, D O" uniqKey="Koralek D" first="D O" last="Koralek">D O Koralek</name><affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Development, Genentech Inc., South San Francisco, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Clinical Development, Genentech Inc., South San Francisco</wicri:regionArea><wicri:noRegion>South San Francisco</wicri:noRegion></affiliation></author><author><name sortKey="Rooney, I" sort="Rooney, I" uniqKey="Rooney I" first="I" last="Rooney">I. Rooney</name><affiliation wicri:level="1"><nlm:affiliation>Product Development Oncology, Genentech Inc., South San Francisco, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Product Development Oncology, Genentech Inc., South San Francisco</wicri:regionArea><wicri:noRegion>South San Francisco</wicri:noRegion></affiliation></author><author><name sortKey="Hsu, J J" sort="Hsu, J J" uniqKey="Hsu J" first="J J" last="Hsu">J J Hsu</name><affiliation wicri:level="1"><nlm:affiliation>Biostatistics, Genentech Inc., South San Francisco, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Biostatistics, Genentech Inc., South San Francisco</wicri:regionArea><wicri:noRegion>South San Francisco</wicri:noRegion></affiliation></author><author><name sortKey="Mckenna, E F" sort="Mckenna, E F" uniqKey="Mckenna E" first="E F" last="Mckenna">E F Mckenna</name><affiliation wicri:level="1"><nlm:affiliation>Medical Affairs, Genentech, Inc., South San Francisco, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Medical Affairs, Genentech, Inc., South San Francisco</wicri:regionArea><wicri:noRegion>South San Francisco</wicri:noRegion></affiliation></author><author><name sortKey="Mcarthur, G A" sort="Mcarthur, G A" uniqKey="Mcarthur G" first="G A" last="Mcarthur">G A Mcarthur</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28444112</idno><idno type="pmid">28444112</idno><idno type="doi">10.1093/annonc/mdx040</idno><idno type="wicri:Area/PubMed/Corpus">000D02</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000D02</idno><idno type="wicri:Area/PubMed/Curation">000C99</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000C99</idno><idno type="wicri:Area/PubMed/Checkpoint">000C99</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000C99</idno><idno type="wicri:Area/Ncbi/Merge">004695</idno><idno type="wicri:Area/Ncbi/Curation">004695</idno><idno type="wicri:Area/Ncbi/Checkpoint">004695</idno><idno type="wicri:Area/Main/Merge">000994</idno><idno type="wicri:Area/Main/Curation">000999</idno><idno type="wicri:Area/Main/Exploration">000999</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study.</title><author><name sortKey="Dreno, B" sort="Dreno, B" uniqKey="Dreno B" first="B" last="Dréno">B. Dréno</name><affiliation wicri:level="3"><nlm:affiliation>Department of Dermato Cancerology, Nantes University, Nantes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Dermato Cancerology, Nantes University, Nantes</wicri:regionArea><placeName><region type="region">Pays de la Loire</region><region type="old region">Pays de la Loire</region><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name sortKey="Ribas, A" sort="Ribas, A" uniqKey="Ribas A" first="A" last="Ribas">A. Ribas</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medicine, Hematology/Oncology, Jonsson Comprehensive Cancer Center, The University of California, Los Angeles, Los Angeles, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Hematology/Oncology, Jonsson Comprehensive Cancer Center, The University of California, Los Angeles, Los Angeles</wicri:regionArea><placeName><settlement type="city">Los Angeles</settlement><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Larkin, J" sort="Larkin, J" uniqKey="Larkin J" first="J" last="Larkin">J. Larkin</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medicine, Royal Marsden NHS Foundation Trust, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Medicine, Royal Marsden NHS Foundation Trust, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Ascierto, P A" sort="Ascierto, P A" uniqKey="Ascierto P" first="P A" last="Ascierto">P A Ascierto</name><affiliation wicri:level="1"><nlm:affiliation>Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori Fondazione G. Pascale, Naples</wicri:regionArea><wicri:noRegion>Naples</wicri:noRegion></affiliation></author><author><name sortKey="Hauschild, A" sort="Hauschild, A" uniqKey="Hauschild A" first="A" last="Hauschild">A. Hauschild</name><affiliation wicri:level="3"><nlm:affiliation>Department of Dermatology, University Hospital Schleswig-Holstein, Kiel, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Dermatology, University Hospital Schleswig-Holstein, Kiel</wicri:regionArea><placeName><region type="land" nuts="2">Schleswig-Holstein</region><settlement type="city">Kiel</settlement></placeName></affiliation></author><author><name sortKey="Thomas, L" sort="Thomas, L" uniqKey="Thomas L" first="L" last="Thomas">L. Thomas</name><affiliation wicri:level="1"><nlm:affiliation>Department of Dermatology, Centre Hospitalier Lyon Sud, Lyon 1 University, Lyons Cancer Research Center, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Dermatology, Centre Hospitalier Lyon Sud, Lyon 1 University, Lyons Cancer Research Center</wicri:regionArea><wicri:noRegion>Lyons Cancer Research Center</wicri:noRegion><wicri:noRegion>Lyons Cancer Research Center</wicri:noRegion></affiliation></author><author><name sortKey="Grob, J J" sort="Grob, J J" uniqKey="Grob J" first="J-J" last="Grob">J-J Grob</name><affiliation wicri:level="3"><nlm:affiliation>Dermatology and Cutaneous Oncology, Aix-Marseille University Hôpital de la Timone AP-HM, Marseille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Dermatology and Cutaneous Oncology, Aix-Marseille University Hôpital de la Timone AP-HM, Marseille</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Koralek, D O" sort="Koralek, D O" uniqKey="Koralek D" first="D O" last="Koralek">D O Koralek</name><affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Development, Genentech Inc., South San Francisco, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Clinical Development, Genentech Inc., South San Francisco</wicri:regionArea><wicri:noRegion>South San Francisco</wicri:noRegion></affiliation></author><author><name sortKey="Rooney, I" sort="Rooney, I" uniqKey="Rooney I" first="I" last="Rooney">I. Rooney</name><affiliation wicri:level="1"><nlm:affiliation>Product Development Oncology, Genentech Inc., South San Francisco, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Product Development Oncology, Genentech Inc., South San Francisco</wicri:regionArea><wicri:noRegion>South San Francisco</wicri:noRegion></affiliation></author><author><name sortKey="Hsu, J J" sort="Hsu, J J" uniqKey="Hsu J" first="J J" last="Hsu">J J Hsu</name><affiliation wicri:level="1"><nlm:affiliation>Biostatistics, Genentech Inc., South San Francisco, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Biostatistics, Genentech Inc., South San Francisco</wicri:regionArea><wicri:noRegion>South San Francisco</wicri:noRegion></affiliation></author><author><name sortKey="Mckenna, E F" sort="Mckenna, E F" uniqKey="Mckenna E" first="E F" last="Mckenna">E F Mckenna</name><affiliation wicri:level="1"><nlm:affiliation>Medical Affairs, Genentech, Inc., South San Francisco, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Medical Affairs, Genentech, Inc., South San Francisco</wicri:regionArea><wicri:noRegion>South San Francisco</wicri:noRegion></affiliation></author><author><name sortKey="Mcarthur, G A" sort="Mcarthur, G A" uniqKey="Mcarthur G" first="G A" last="Mcarthur">G A Mcarthur</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author></analytic><series><title level="j">Annals of oncology : official journal of the European Society for Medical Oncology</title><idno type="eISSN">1569-8041</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In the coBRIM phase III trial, the addition of cobimetinib, an MEK inhibitor, to vemurafenib, a BRAF inhibitor, significantly improved progression-free survival [hazard ratio (HR), 0.58; P < 0.0001] and overall survival (HR, 0.70; P = 0.005) in advanced BRAF-mutated melanoma. Here, we report on the incidence, course, and management of key adverse events (AEs) in the coBRIM study.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>France</li><li>Italie</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Californie</li><li>Grand Londres</li><li>Pays de la Loire</li><li>Provence-Alpes-Côte d'Azur</li><li>Schleswig-Holstein</li><li>Victoria (État)</li></region><settlement><li>Kiel</li><li>Londres</li><li>Los Angeles</li><li>Marseille</li><li>Melbourne</li><li>Nantes</li></settlement></list><tree><country name="France"><region name="Pays de la Loire"><name sortKey="Dreno, B" sort="Dreno, B" uniqKey="Dreno B" first="B" last="Dréno">B. Dréno</name></region><name sortKey="Grob, J J" sort="Grob, J J" uniqKey="Grob J" first="J-J" last="Grob">J-J Grob</name><name sortKey="Thomas, L" sort="Thomas, L" uniqKey="Thomas L" first="L" last="Thomas">L. Thomas</name></country><country name="États-Unis"><region name="Californie"><name sortKey="Ribas, A" sort="Ribas, A" uniqKey="Ribas A" first="A" last="Ribas">A. Ribas</name></region><name sortKey="Hsu, J J" sort="Hsu, J J" uniqKey="Hsu J" first="J J" last="Hsu">J J Hsu</name><name sortKey="Koralek, D O" sort="Koralek, D O" uniqKey="Koralek D" first="D O" last="Koralek">D O Koralek</name><name sortKey="Mckenna, E F" sort="Mckenna, E F" uniqKey="Mckenna E" first="E F" last="Mckenna">E F Mckenna</name><name sortKey="Rooney, I" sort="Rooney, I" uniqKey="Rooney I" first="I" last="Rooney">I. Rooney</name></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Larkin, J" sort="Larkin, J" uniqKey="Larkin J" first="J" last="Larkin">J. Larkin</name></region></country><country name="Italie"><noRegion><name sortKey="Ascierto, P A" sort="Ascierto, P A" uniqKey="Ascierto P" first="P A" last="Ascierto">P A Ascierto</name></noRegion></country><country name="Allemagne"><region name="Schleswig-Holstein"><name sortKey="Hauschild, A" sort="Hauschild, A" uniqKey="Hauschild A" first="A" last="Hauschild">A. Hauschild</name></region></country><country name="Australie"><region name="Victoria (État)"><name sortKey="Mcarthur, G A" sort="Mcarthur, G A" uniqKey="Mcarthur G" first="G A" last="Mcarthur">G A Mcarthur</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000999 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000999 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:28444112
|texte= Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:28444112" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |